论文部分内容阅读
目的:评价喜炎平与利巴韦林联用治疗小儿手足口病患者的临床疗效和安全性。方法:选取2012年3月-2015年2月间收治的手足口病患儿69例,根据用药不同将其分成治疗组(37例)和对照组(32例);对照组患者均给予单用利巴韦林治疗,治疗组患者在对照组治疗基础上加用喜炎平治疗,评价两组患者临床后的总有效率和不良反应的发生率。结果:治疗后,治疗组患者临床总有效率为94.60%,优于对照组为81.25%(P<0.05);退热时间、疱疹消失时间及治愈时间均优于对照组(P<0.05);肝功能损伤率、肌钙蛋白转阴率和其他不良反应的发生率优于对照组(P<0.05)。结论:小儿手足口病患者的治疗,采用喜炎平与利巴韦林联用治疗,其临床疗效较确切,不良反应较轻,安全性较高,优于单用利巴韦林治疗。
Objective: To evaluate the clinical efficacy and safety of Xiyanping combined with ribavirin in treating children with hand-foot-mouth disease. Methods: 69 children with hand-foot-mouth disease were selected from March 2012 to February 2015. The patients were divided into treatment group (37 cases) and control group (32 cases) according to different drugs. Patients in control group were given single Ribavirin treatment, the treatment group patients in the control group based on the use of Xiyanping treatment, evaluation of the two groups of patients after the clinical total efficiency and adverse reactions. Results: After treatment, the total effective rate of the treatment group was 94.60%, which was 81.25% better than that of the control group (P <0.05). The time of fever relief, disappearance of herpes and the healing time were all better than those of the control group (P <0.05). The incidence of hepatic impairment, troponin and other adverse reactions was better than that of the control group (P <0.05). Conclusion: The treatment of children with hand-foot-mouth disease, the combination of Xiyanping and ribavirin treatment, the more accurate clinical efficacy, less adverse reactions, higher safety, better than ribavirin alone.